Vilobelimab + BSC | BSC | |
---|---|---|
Characteristics | ||
n | 8 | 9 |
Sex = male (%) | 5 (62.5) | 6 (66.7) |
Age | 61.5 [51.0, 61.5] | 61.0 [55.0, 68.0] |
Body-mass index | 27.3 [24.4, 31.1] | 29.0 [25.8, 30.6] |
Race (%) | ||
Asian | 4 (50.0) | 2 (22.2) |
Black or African American | 2 (25.0) | 2 (22.2) |
White | 2 (25.0) | 5 (55.6) |
Days since onset of COVID-19 symptoms | 11.00 [7.5, 11.5] | 13.0 [12.0, 14.0] |
Medical history | ||
Asthma or other chronic pulmonary disease | 2 (25.0) | 0 (0.0) |
Cardiac disorders | 3 (37.5) | 1 (11.1) |
Diabetes mellitus type 2 | 3 (37.5) | 2 (22.2) |
Hypertension | 4 (50.0) | 2 (22.2) |
Obesity | 2 (25.0) | 4 (44.4) |
Number of comorbidities | 2.5 [1.0, 3.3] | 2.0 [1.0, 2.0] |
Patients with relevant comorbidities | 7 (87.5) | 5 (55.6) |
Disease severity | ||
Intubated at randomization | 6 (75.0) | 8 (88.9) |
On ICU at randomization | 6 (75.0) | 8 (88.9) |
qSOFA | 1.0 [0.8, 1.3] | 1.0 [1.0, 2.0] |
MEWS | 3.5 [2.0, 5.3] | 4.0 [4.0, 6.0] |
Previous medication | ||
Antibiotics | 8 (100.0) | 7 (77.8) |
Chloroquine | 1 (12.5) | 2 (22.2) |
Remdesivir | 0 (0.0) | 0 (0.0) |
Steroids | 2 (25.0) | 1 (11.1) |